Cristina M. Tello-Ramo
Badalona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Causal effects of multiple sclerosis therapies in left-truncated registry data.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 21, 2026
Posterior Circulation Ischemic Stroke Occurring After ChAdOx1 nCoV-19/AZD1222 Vaccination Without Evidence of Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Case Report and Focused Narrative Review.
Journal: Journal of clinical medicine
Published: June 16, 2026
Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing.
Journal: Frontiers in immunology
Published: May 12, 2026
Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.
Journal: International journal of molecular sciences
Published: April 15, 2026
Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].
Journal: Multiple sclerosis and related disorders
Published: April 10, 2026
Development of a New Patient-Reported Outcome to Measure Fatigue in Patients with Multiple Sclerosis.
Journal: Nursing reports (Pavia, Italy)
Published: January 28, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 13, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.
Journal: Journal of neurology
Published: November 01, 2025
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.
Journal: CNS drugs
Published: September 04, 2025
Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study.
Journal: Multiple sclerosis and related disorders
Published: August 27, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: March 25, 2025
Last Updated: 09/26/2026